Registration Deadline:
Vanderbilt Contact:
More Information:
Explore other Industry Opportunities:
Asahi Kasei Pharma, a global pharmaceutical company, is seeking preclinical drug candidates for specific transplant-related complications. The company is looking for candidates with demonstrated in vitro efficacy, ideally supported by in vivo data from relevant animal models.
Approaches of interest
- High priority indications include transplant rejection, antibody-mediated rejection, delayed graft function, and several other transplant-related complications
- Biologics, small molecules, peptides, and RNA-based approaches
- Novel drug candidates intended for use in combination with existing drugs
Out of scope
- Drug repurposing
- Cell therapy, probiotics, gene editing, and AAV therapy
- Diagnostic products, medical devices, platform technologies
- Projects focused solely on understanding mechanisms or exploring new targets
Developmental stage of interest: Opportunities from preclinical research phase to late preclinical research stage are considered, provided efficacy has been confirmed in in vitro studies reflecting the treatment concept. In vivo data from animal models is highly desirable.
Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.